NPCs, edited to contain specific ES cell transcription factor motif deletions. DNA hydroxyl-methylation of enhancers in ES cells, determined by ES cell transcription factors, may serve as a potential molecular memory for subsequent enhancer activation in mature macrophages. These findings suggest that the massive repertoire of cell-type-restricted enhancers are essentially hierarchically and obligatorily premarked by binding of a defining ES cell transcription factor in ES cells, dictating the robustness of enhancer activation in mature cells.
bind to macrophage enhancers in open chromatin configurations, we profiled the distribution of several of the most important ES cell transcription factors-ESRRB, NANOG, OCT4 and SOX2 (ENOS)-in a −1 kb/+ 1 kb window, ensuring that we were exclusively analysing macrophage-restricted enhancers. Notably, 6,775 macrophage-restricted enhancers showed binding of ENOS ( Fig. 1c) . We established the specificity of ENOS binding in macrophage-restricted enhancers by comparing with random regions (Extended Data Fig. 1c ), which revealed statistically significant binding of ESRRB (Extended Data Fig. 1d ). Notably, about 80% of macrophage-restricted enhancers were bound by only one or at most two ES cell transcription factors, whereas ES cell-active enhancers were bound by all four ENOS factors (Fig. 1d , Extended Data Fig. 1e ), as exemplified by genome browser images (Extended Data Fig. 1f ). We also analysed 12 ES cell transcription factors from the published literature 7 , and found that active ES cell-restricted enhancers were characteristically bound predominantly by about 4-8 of the 12 ES cell transcription factors evaluated (OCT4, SOX2, NANOG, ESRRB, SMAD1, E2F1, TCFCP2L1, ZFX, STAT3, KLF4, C-MYC and N-MYC), consistent with their reported cooperative binding 7, 8 , while the majority of the active macrophage-restricted enhancers exhibited binding of only one or two of these factors (Fig. 1e) .
To determine whether cell-type-restricted enhancers in other cell types also exhibit similar pre-marking, we examined cell-typerestricted enhancers from heart, kidney and N2A neuronal cells in a mouse model. These enhancers in ES cells again predominantly exhibited binding of a single ENOS factor and chromatin openness (Extended Data Fig. 2a-d) .
Given the established role of the cohesin complex in chromatin architecture and gene regulation [9] [10] [11] , we investigated whether this complex has a role in premarked enhancers. Consistent with a previous report 11 , cohesin was colocalized with ENOS-bound regions ( Fig. 2e ). Therefore, we next investigated whether premarked enhancers could interact with other genomic regions. We performed circular chromatin conformation capture followed by deep sequencing (4C-seq) on a macrophage enhancer located 5′ of Il1a 12 . This premarked enhancer interacted specifically with other genomic regions in ES cells, including an upstream CTCF-bound site, but not with the cognate promoter. In macrophages treated with the bacterial endotoxin Kdo2-lipid A (KLA), this enhancer interacts robustly with the cognate promoter of the target coding gene (Extended Data Fig. 3a ). An enhancer located 5′ of Tnfaip3 was similarly found to interact specifically with other genomic regions in ES cells, but not with its cognate promoter (Extended Data Fig. 3b ). In addition, we performed RNA sequencing (RNA-seq) and examined the proximal macrophage-expressed genes of 6,775 macrophagerestricted enhancers. We found 634 differentially expressed genes (fold-change ≥ 4), which corresponded to functional categories relevant to macrophages but not ES cells (Extended Data Fig. 3c, d) . These data, together with the 4C-seq results, suggest that premarked macrophage enhancers are not functional, despite their binding of ES cell transcription factors and open chromatin configurations in ES cells.
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To further explore any potential effect of ENOS binding in ES cells on the subsequent function of enhancers bound by PU.1 (also known as SPI1), a key macrophage transcription factor, we assessed the physical locations of ENOS binding in premarked enhancers. The locations of ENOS binding with respect to PU.1 binding sites varied in the 6,775 macrophage enhancers, corresponding to the locations of cognate binding sites ( Fig. 2a ).
Because enhancer RNA (eRNA) expression is a mark of enhancer activity 13 , we investigated whether transcription units were present in ENOS-bound premarked enhancers. Because global run-on sequencing (GRO-seq) data on these enhancer regions were insufficiently robust to draw clear conclusions, we performed precision nuclear run-on sequencing for RNA polymerase II initiation sites (PRO-cap). We identified 2,336 significant RNA polymerase II initiation sites (cap sites) in −1 kb/+ 1 kb windows around 6,775 premarked enhancers in ES cells. While cap sites were found to be located close to PU.1 binding sites in macrophages, they were located at various distances from PU.1 sites in ES cells (Fig. 2b) . The median distance from the PU.1 site to the macrophage-specific eRNA cap (−500 bp/+ 500 bp from the PU.1 site) was about 105 bp in mature macrophages 13 , whereas the median distance from the ENOS binding site to the ES cell-specific eRNA cap was about 165 bp (Fig. 2c ). The ES cell-induced transcription unit for each enhancer was therefore distinct from the eRNA transcription units subsequently nucleated by PU.1 and C/EBPα in mature macrophages, the binding sites for which are located within a core enhancer region.
Indeed, ATAC-seq revealed chromatin openness in the region where ENOS bound to the enhancers (Fig. 2d ). We investigated the functional correlation between cohesin and ENOS-bound enhancers, and found that high RAD21 binding was associated with high ENOS binding and a more open configuration ( Fig. 2f ).
To address any concerns regarding serum culture conditions, we performed chromatin immunoprecipitation with sequencing (ChIPseq) with H3K4me2 and H3K27Ac, and ATAC-seq under two different culture conditions: with inhibitors of MEK and GSK3 (2i) and with serum. H3K4me2 and H3K27Ac were not observed in macrophage enhancers in either 2i-or serum-cultured ES cells, and the ATAC-seq signal was equivalently detected in both conditions (Extended Data Fig. 4a, b ), indicating that culturing ES cells in serum did not affect our observations. Indeed, most pluripotency-associated genes were transcribed at similar levels in serum-and 2i-cultured ES cells 14 and only 8% of serum-treated ES cells were heterogeneous 15 .
To investigate the potential function of premarking, we examined the correlation between ENOS factors and the ultimate activity of the enhancers in mature macrophages. ENOS-bound macrophage enhancers with the highest or lowest approximately 20% levels of ENOS transcription units were selected to test their ultimate activation in macrophages. The highest group of enhancers exhibited higher activation, as determined by binding of PU.1, PRO-cap signal, eRNA transcription, levels of H3K4me2 and H3K27Ac, and binding of cohesin in macrophages ( Fig. 3a-d ). In addition, when the highest or lowest approximately 20% of active macrophage enhancers were extracted using GRO-seq signal in macrophages 13 , ENOS binding and ATAC-seq signals in ES cells were higher in the most active macrophage enhancers than in the least active macrophage enhancers (Fig. 3e, f) . 
Indeed, putatively active macrophage enhancers, defined by eRNA transcription, were found much more frequently in the 6,775 ENOSbound enhancers than in the 11,630 macrophage enhancers that do not bind ENOS in a −1 kb/+ 1 kb window (Fig. 3g ). The correlation between premarking and enhancer robustness was confirmed in other tissues: spleen, lung, cortex and bone marrow (Extended Data Fig. 5a-d ). We next investigated whether the binding of these factors in ES cells had a direct role in the ultimate activation of cell-typerestricted enhancers in mature macrophages, choosing premarked macrophage-restricted enhancers linked to coding target genes that would not be predicted to influence macrophage development. We first selected a putative enhancer near the Tlr1 locus, and then used CRISPR-Cas9 technology in ES cells to selectively delete the ESRRB binding site, followed by differentiation 16 (Extended Data Fig. 6b ). Mature macrophages were selected on the basis of their ability to adhere to the non-adherent culture plates, as confirmed by expression of CD11B and F4/80 (Extended Data Fig. 6a ). This permitted only a limited harvest of mature macrophages, thus precluding global genomic analyses. Notably, three independently derived individual clonal lines (#3, #10 and #14) were sequence-proven to harbour a 8-bp deletion of the ESRRB site in the Tlr1 enhancer (Extended Data Fig. 6c, d) . Consistent with the confirmed deletion, ESRRB binding in ES cells was decreased in these mutant clones compared to wild-type clones (Fig. 4a ). The mutant clonal cells were differentiated into macrophages with an equivalent efficiency to that of wild-type cells; qualitative PCR with ChIP (ChIP-qPCR) for PU.1 and H3K4me2 was performed, and eRNA transcription was measured in the ES cell-derived macrophages (ESDMs). These analyses revealed that PU.1 binding was inhibited, that eRNA transcription was lost and that there was a consistent decrease in the level of H3K4me2 after deletion of the ESRRB site ( Fig. 4b ).
To corroborate these findings, we constructed mutant clonal cells targeting the Tnfaip3 enhancer with either a 16-bp deletion (#26) or a 21-bp deletion (#45) encompassing the ESRRB binding site (Extended Data Fig. 6e -g), and differentiated them into macrophages. The reduction in PU.1 recruitment, eRNA transcription and H3K4me2 levels in mutant ESDMs correlated with inhibition of ESRRB binding in ES cells ( Fig. 4c, d) . As a control, we tested Tlr1 eRNA transcription in Tnfaip3 mutant cells, observing no change (Extended Data Fig. 6h ). We investigated two other loci, Prdx5 and Nod2, in the same way (Extended Data Fig. 7a, b , e, f) and again found that enhancer activities defined by eRNA transcription were inhibited in mutant ESDMs with loss of ESRRB binding in ES cells, but Prdx5 mutant enhancers (B11, F1, G11) exhibited the same level of Nod2 eRNA transcription as in wild-type cells (Extended Data Fig. 7c, d, g) . Because modifying the genomic and mutant clones of Tlr1 (a; #3, #10, #14) and Tnfaip3 (c; #26, #45) in ES cells. One example of representative data is shown (n ≥ 2 biological repeats). b, d, PU.1 binding, eRNA transcription, and H3K4m2 level in wild-type and mutant clones of Tlr1 (b) and Tnfaip3 (d) in ESDMs. Each dot indicates a biological experiment (n ≥ 3 biological repeats from two pooled different experiments, n = 2 biological repeats from two pooled different experiments for #45 for H3K4me2 ChIP-qPCR). e, Promoter activities in native full-length Tlr1 enhancer response to wild-type versus ESRRB-deleted mutant in Raw264.7 cells (n = 5 biological repeats). f, Mapping of DNA methylation modification (5mC and 5hmC) and binding of TET1 in 6,775 premarked-macrophage enhancers in a −1 kb/+ 1 kb window centred on PU.1. g, 5-hmC in LSK (LT-HSC, ST-HSC, MPP: long term-and short term-hematopoietic stem cells, multipotent progenitors), CMP (common myeloid progenitors) and GMP (granulocyte macrophage progenitors) in 6,775 premarked enhancers in −3 kb/+ 3 kb window centred on PU.1. In the box plots, line shows median, and box shows 25th and 75th percentiles. P values calculated using Welch's two-sided t-test. Data from published sources are listed in Supplementary Table 1 . Primer sets are listed in Supplementary Table 2 .
Letter reSeArCH locus could potentially result in different genetic events, we performed RNA-seq in Tlr1 enhancer clonal cells. Normal ES cells and clonal ES cells (wild-type, #10 and #14) exhibited the same pattern of transcription in the Tlr1 locus (Extended Data Fig. 6i ).
Enhancers harbouring the ESRRB core site deletion were evaluated by luciferase reporter assay to test whether genomic sequence disruption had impaired enhancer function compared to wild-type enhancers in macrophages. The mutant enhancers were equally competent to increase reporter expression as the wild-type enhancer in immortalized Raw 264.7 macrophages (Fig. 4e) , confirming that the inhibitory effects in Tlr1 mutant ESDMs resulted from inhibition of ESRRB binding in ES cells.
We further investigated this functional linkage in neural precursor cell (NPC)-restricted enhancers in the Nek1 locus and Ankrd1 locus (referred to as N4 and N8, respectively). Sox2 and Esrrb bound to N4 and Esrrb bound to N8, and we targeted the Sox2 or Esrrb binding site, in N4 or N8, respectively, for deletion (Extended Data Fig. 8a, d ). Clonal ES cells were differentiated to NPCs in N2B27 medium for 6 days, with more than 70% of cells exhibiting the green signal caused by knock-in of the Sox1-GFP reporter in ES cells 17 . NPC differentiation was further confirmed by qRT-PCR of ES cell-specific genes (Oct4, Esrrb and Nanog) and NPC-specific genes (Sox1, Fgf5, Nestin and Pax6) (Extended Data Fig. 8g ). Transcription of N4 or N8 eRNA was inhibited in N4-or N8-mutant ES cell-derived NPCs, respectively, correlating with inhibition of ESRRB binding in ES cells (Extended Data Fig. 8b, e ). SOX2 binding could not be assessed because the anti-SOX2 IgG was ineffective. The specificity of N4-or N8-mutant clones on inhibition of eRNA transcription was confirmed by testing eRNA transcription in the N8 locus in N4 mutant cells, or the N4 locus in N8 mutant cells (Extended Data Fig. 8c , f). Collectively, these analyses corroborate the functional importance of ES cell factor premarking in both macrophage-restricted and NPC-restricted enhancers.
Poised enhancers, another class of well-studied cell-type-specific enhancer that is marked in ES cells, are often found near lineagedetermining factors 18, 19 . The 214 macrophage enhancers exhibit poised chromatin signatures (Extended Data Fig. 1a ) with binding of about 2-4 ENOS factors in the enhancer cores in ES cells (Extended Data Fig. 9a, b ). For example, we noted that Spi1 (which encodes PU.1) has four clustered enhancers with poised chromatin signatures in ES cells. In contrast to the two enhancers (Enh2 and Enh3) that are active in mature macrophages, the other two (Enh1 and Enh4), which are bound by ESRRB and OCT4, are not (Extended Data Fig. 9c, d ). These two premarked enhancers in ES cells might participate in the early activation of Spi1, which is known to exhibit a positive feedback loop on the two PU.1-bound enhancers 20 .
A particularly intriguing question is how the marking of future celltype-restricted enhancers might be 'remembered' for their ultimate activation later in development. Published results and analysis of the mRNA levels of the ENOS factors suggest that the temporal pattern of disappearance of these factors virtually coincides with the appearance of the first lineage-determining factors, TAL1, GATA2 and RUNX1, followed by the appearance of PU.1 and C/EBPα, which initiate macrophage enhancer activation 21 (Extended Data Fig. 10a ). Another potential explanation is that binding of one of the ES cell transcription factors to the future cell-type-restricted enhancers might be accompanied by a specific DNA demethylation event that serves to ensure that an enhancer remains accessible to transcription factors, the binding of which may be impaired by DNA methylation. We therefore analysed available data regarding DNA methylation in ES cells, and found the 5-hydroxymethylcytosine (5-hmC) mark and the enzyme responsible for that mark, TET1, in the 6,775 premarked macrophage enhancers (Fig. 4f) , reflecting the presence of TET1 in a complex with ESRRB and OCT4 22 . Notably, knockdown of Esrrb reduced 5-hmC levels in ESRRB-bound macrophage enhancers in ES cells (Extended Data Fig. 10b ). To investigate whether 5-hmC is maintained during differentiation, such that it could serve as a marker for molecular memory, we examined 5-hmC during haematopoiesis using published data 23 , and found that 5-hmC was maintained during haematopoiesis ( Fig. 4g , Extended Data Fig. 10c ). The enhancer histone marks, H3K4me1 and H3K27Ac, were studied during haematopoiesis 24 , but not found in ES cells, or even in mesoderm, being gained gradually early in haematopoiesis (Extended Data Fig. 10c, d) .
Investigation of the signature of cell-type-restricted enhancers in ES cells has provided an insight into the process of genomic enhancer recognition in ES cells underlying cell-type-specific transcriptional programs. Furthermore, the marking of the cell-type-restricted enhancers in ES cells license the ultimate robust activation of the celltype-restricted enhancer in mature differentiated cells (Extended Data Fig. 10e ).
Online content
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Cell culture. 46c mouse ES cells were a gift from A. Smith. Cells were grown in feeder-free conditions as previously described 17 . ES cells were maintained in serum culture medium with DMEM-KO (Invitrogen 10829-018) supplemented with 15% ES cell qualified-fetal bovine serum (Omega, FB-05), 2 mM nonessential amino acids (Invitrogen 11140-050), glutamax (Invitrogen 35050061), penicillin/ streptomycin (Invitrogen 15140122), 2-mercaptoethanol (Sigma, M7522) and 1,000 U/ml LIF (ESGRO, ESG1106). ES cells in 2i medium were grown in N2/ B27 medium with 50% neurobasal (Gibco 21103-049) and 50% DMEM/F12 (Invitrogen 21331-020), 2 mM nonessential amino acids, glutamax, penicillin/ streptomycin, 2-mercaptoethanol, N2 supplement (Invitrogen, 175020-01), B27 (Invitrogen, 17504-001), 1,000 U/ml LIF, and 2i (ESGRO, ESG1121). Cells were regularly checked for mycoplasma contamination (Lonza, LT07-318). Peritoneal macrophages were obtained from 6-8-week-old female C57BL/6 J mice (Jackson laboratory). Mice were injected with thiogycollate for 3-4 days, and macrophages were obtained and cultured in RPMI supplemented with 10% FBS and penicillin/ streptomycin overnight before collection. All animal care and experimental procedures were in accordance with the University of California, San Diego research guidelines for the care and use of laboratory animals. Antibodies. Antibodies used for ChIP and ChIP-seq included: RAD21 (Abcam, ab992), H3K4me2 (Upstate, 07-030), PU.1 (Santa Cruz, sc-352) and H3K27Ac (Active Motif, 39133); for immunostaining, F4/80-FITC (eBioscience, 11-4801-81) and CD11b-PE-Cyanine5 (eBioscience, 15-0112-81); for MeDIIP, 5-hmC (Active Motif, #39769). Enhancer reporter assay. For construction of Tlr1 enhancer reporter plasmids, 600 bp of Tlr1 locus spanning the ESRRB binding site was PCR amplified and cloned into pGL4.23 at the KpnI/XhoI sites downstream of the luciferase reporter gene controlled by a minimal promoter. Enhancer reporters were transfected into RAW264.7 macrophages using Lipofectamine 3000 (Invitrogen), using 200 ng of enhancer reporter and 5 ng of Renilla. Luciferase activity was measured 48 h after transfection using a Veritas microplate luminometer (Turner Biosystems) and normalized to Renilla activity to correct for differences in transfection efficiency. ES cell differentiation to macrophages. ES cell differentiation to macrophages was performed as previously described 16 . In brief, ES cells were trypsinized and transferred to bacteriological plates in macrophage differentiation medium, which has 15% L929 conditioned medium and 1 ng/ml IL3 but lacks LIF, for about 6-8 days to make embryoid bodies (EBs). EBs were transferred onto gelatin-coated tissue culture dishes for about 3-4 days. After that, supernatants of adherent EBs containing floating macrophage progenitors were collected and plated onto bacteriological dishes for 7 days to obtain adherent macrophages in macrophage differentiation medium, which has 15% L929 conditioned medium. Medium was readded to the adherent EB plates and macrophage progenitors were obtained every 2 days. ES cell differentiation to NPCs. ES cell differentiation to NPCs was performed as previously described 17 . In brief, ES cells were trypsinized, plated onto gelatincoated plates and cultured in N2B27 medium for 6 days. On day 6, > 70% green-signal expressing cells were observed, which indicates differentiation into NPCs, and cells were collected for further experimental analysis. CRSIPR-Cas9 assay. Online software (http://crispr.mit.edu) was used to design optimal candidate sgRNAs to target proximal regions of ES cell transcription factor motifs, and these sgRNAs were cloned to vector PX459 (Addgene #48139), which co-expresses sgRNA and Cas9. This plasmid was transfected into ES cells with Lipofectamine 2000 and 1.0 µg/ml puromycin was added 2 days after transfection. Cells were cultured for another 3 days then diluted to pick up single-cell-derived clonal lines. DNA was extracted from these cells and PCR was performed to amplify fragments containing sgRNA-targeted ES cell transcription factor (ESRRB or SOX2) motifs. Sequencing was applied to identify clones in which the ESRRB or SOX2 motif was mutated or deleted. sgRNA sequences and primer sequences are listed in Supplementary Table 2 . RNA preparation and qRT-PCR. RNA was isolated using Trizol (Invitrogen) or RNeasy kit (Qiagen). RNA was reverse transcribed using SuperScript III Reverse Transcriptase kit (Invitrogen). Quantitative PCR was performed using SYBR Green Master Mix (Biorad). The experiments were repeated at least three times as biological replicates and P values were obtained using Welch's two-sided t-test. Primers are listed in Supplementary Table 2 . RNA-seq. RNA-seq libraries were made from 1 µg DNase-treated total RNA using TruSeq stranded mRNA Library Prep Kit (Illumina, RS-122-2101, RS-122-2102) according to the manufacturer's instructions. RNA-seq libraries were quantified with Qubit, clustered and sequenced using HiSeq 3000/4000 SR cluster kit (Illumina GD-410-1001) and HiSeq 3000/4000 SBS kit (Illumina FC-410-1001). RNA-seq reads were counted using HOMER software considering only exonic regions for RefSeq genes. The proximal macrophage-expressed genes of 6,775 macrophage-restricted enhancers were examined and further analysis was performed to obtain differentially expressed genes using the following criteria: FC ≥ 4, over 20 tags in macrophage, and visualized by heat map with log 2 transform. Gene ontology analysis and genetic association analysis were performed using Metascape (http://metascape.org). PRO-cap. Pro-cap and library preparation for sequencing have previously been described 25 . Nuclei were prepared from ~40 million cells for run-on assay. Run-on reactions were stopped and RNA was extracted with Trizol LS reagent (Invitrogen). Following DNase treatment, the RNA was fragmented. Biotin-incorporated fragmented RNA was immunoprecipitated with anti-strepavidin beads (Invitrogen). Then the RNA was treated with polynucleotide kinase (Enzymatics) and precipitated. The RNA was dephosphorylated with calf intestinal phosphatase (NEB) and 5′-de-capped with tobacco acid pyrophosphatase (Epicentre). The reaction was stopped and RNA was extracted with Trizol LS, and libraries were prepared by ligating Illumina TruSeq-compatible adapters to the RNA 3′ and 5′ ends with truncated mutant RNA ligase 2 (K227Q) and RNA ligase 1 (NEB), respectively, followed by reverse transcription, cDNA isolation and PCR amplification. Final libraries were size selected on TBE gels to 60-110-bp insert size. Pro-cap results were trimmed to remove A-stretches originating from the library preparation. Each sequence tag returned by the Illumina Pipeline was aligned to the mm9 assembly using Bowtie2 allowing up to three mismatches. Only tags that mapped uniquely to the genome were considered for further analysis. Each sequencing experiment was normalized to a total of 10 7 uniquely mapped tags by adjusting the number of tags at each position in the genome to the correct fractional amount given the total tags mapped. ChIP-seq. Cells were fixed with 2 mM disuccinimidyl glutarate (DSG) (proteochem) for 45 min and 1% formaldehyde for 10 min, and quenched using glycine for 5 min. Nucleus lysates were prepared using sonication buffer with 1% SDS, and immunoprecipitation was performed with several different antibodies. After overnight incubation with antibodies, beads were added for another 3 h, and washing was performed. Reverse-crosslinking was done overnight at 65 °C and DNA was purified using QIAquick Spin column (Qiagen). For ChIP-seq, extracted DNA was ligated to adaptors and deep sequencing was performed with Illumina's HiSeq 2000, 2500, or 4000 system according to the manufacturer's instructions. The first 48 bp of each sequence tag returned by the Illumina Pipeline was aligned to the mm9 assembly using BFAST or Bowtie2. Only uniquely mapped tags were selected for further analysis. The data were visualized by preparing custom tracks on the UCSC genome browser using HOMER. Genomic binding peaks for transcription factors were identified using the findPeaks.pl command from HOMER with eightfold enrichment over the input sample, fourfold enrichment over local background, a minimal tag number of 16, and normalization to 10 7 mapped reads per experiment. For histone marks, initial seed regions of 500 bp were considered to calculate enriched reads.
Regions of maximal density exceeding a given threshold with FDR < 0.001 were called as peaks. Peaks within ± 1,000 bp of from the RefSeq gene transcription start site were considered to be promoters, and to focus the analysis on enhancers, peaks within 3 kb of a gene promoter were filtered out. 4C-seq. Chromosome confirmation capture was performed as previously described 12 . In brief, 10 million cells were cross-linked with 1% formaldehyde for 10 min and quenched with glycine for 5 min on ice. Soluble chromatin was incubated with 400 U HindIII (NEB) overnight at 37 °C, and then intramolecular ligations were performed using 1,000 U T4 DNA ligase (NEB) for 4 h at 16 °C under dilution. Chromatin was decrosslinked at 65 °C and then treated with RNase to remove RNA before purification using several phenol and phenol-chloroform extractions and ethanol precipitation. The second restriction digestion was also performed overnight at 37 °C, using 50 U DpnII (NEB). DNA was ligated overnight and purified as before and ultimately using Qiagen columns and subjected to inverse PCR (Expand Long-Range PCR system; Roche Diagnostics) using a first primer designed on the viewpoint near a HindIII site and a second outer primer designed beside the DpnII site. Both primers contained Illumina sequencing adapters and barcodes for multiplexing. PCR samples were purified using a Roche kit and quantified using a Qubit.
We analysed data using a previously described bioinformatics pipeline 12 . MeDIP-seq. Genomic DNA for hMeDIP was isolated from cells using Qiagen's DNeasy Blood and Tissue Kit. Isolated genomic DNA was then fragmented to 100-300 bp through sonication using Diagenode's Bioruptor platform and the size distribution was confirmed through gel electrophoresis. Barcoded adaptors for Illumina sequencing were added to 1 µg of fragmented genomic DNA per experiment, using the NEBNext Ultra II DNA Library Prep Kit for Illumina, following the manufacturer's instructions. This protocol was stopped after adaptor ligation and cleanup (and before any amplification steps), and the adaptor ligated fragmented DNA was then used for hydroxy-methylated DNA pulldown. Denaturing, immunoprecipitation, washing, and purification of hydroxy-methylated DNA were performed as previously described 26 , with the following modifications. One microlitre of 5-hmC antibody-containing serum was used per immunoprecipitation reaction. Washing was done five times, with each wash for 15 min at 4 °C. Next, DNA was eluted from beads using 200 µl digestion buffer, incubated overnight with Proteinase K at 50 °C, and purified using Qiagen's QIAquick PCR Purification Kit. Purified hydroxy-methylated genomic DNA was then further processed with NEBNext Ultra II DNA Library Prep Kit for Illumina at the step of PCR enrichment of adaptor-ligated DNA, per the manufacturer's instructions, continuing with the entire protocol to prepare libraries for Illumina sequencing. Data were mapped to mm9 using Bowtie2 with standard settings, and peaks were found by using MACS with default parameters. ATAC-seq. ATAC-seq was performed as previously described 27 . Nuclei were prepared from 50,000 cells and the transposition reaction was performed for 30 min at 37 °C. DNA fragments were amplified by PCR and purified, and deep sequencing was performed with Illumina's HiSeq 2000, 2500, or 4000 system according to the manufacturer's instructions. ATAC-seq data were mapped to mm9 using Bowtie2 with standard settings. Tag directories with reads mapped to the mitochondrial chromosome filtered out were created. ATAC-seq peaks were identified using findPeaks.pl in HOMER with the settings: -style histone -size 75 -minDist 75 -minTagThreshold 6 -L 8 -F 8. BED files were created from Tag directories using the HOMER package. Deep sequencing. For all ChIP-seq, RNA-seq, 4C-seq, ATAC-seq, MeDIP-seq and PRO-cap experiments, the DNA libraries were sequenced for 50 cycles on Illumina's HiSeq 200, 2500 or 4000 system according to the manufacturer's instructions. Sequencing experiments were visualized by preparing custom tracks for the UCSC Genome browser. Bioinformatic characterization of enhancers. The criteria for identifying PU.1-H3K4me2 co-bound enhancer regions was that the distance from the centre of a PU.1 peak to the H3K4me2 peak-occupied region was ≤1 kb. ES cell factor-bound macrophage enhancers were defined by calculating the distance ≤1 kb between ES cell factor peak-spanning regions and PU.1 bound macrophage enhancers. The active ES cell enhancers or active macrophage enhancers were defined using H3K27Ac (over 100 tags) to examine binding of 12 different ES cell factors. The functional macrophage enhancers were defined using GRO-seq (over 20 tags) in macrophages, and these enhancers were used to count the number of functional enhancers in ENOSbound enhancer or non-bound enhancer using a −1 kb/+ 1 kb window. Highly active or less active macrophage enhancers were created after excluding non-active macrophage enhancers using GRO-seq (less than 5 tags) in macrophages. The comparison of tag intensity of ChIP-seq, ATAC-seq, PRO-cap and GRO-seq or distances between different categories are presented as boxplots by using normal scales. P values were calculated using Welch's two-sided t-test. To profile the distribution of ES cell factors surrounding PU.1-H3K4me2 co-bound enhancer regions, ChIP-seq signals surrounding PU.1 peak centres were separated into 40 bins, and then were sorted by the tag numbers based on the distance to the PU.1 peak centre. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. GEO data. The GEO datasets used in this study are listed in Supplementary Table 1 . 
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Extended Data Fig. 1 | Features of macrophage-restricted Supplementary Table 1 .
Extended Data Fig. 7 | Premarking in ES cells is required for robust future macrophage enhancer activation. a, b, Putative Prdx5 enhancer mutant sequence diagram and DNA sequence documentation of several of the homozygous mutation clones, used for analysis. c, Three mutant clones (B11, F1, G11) of the putative Prdx5 enhancer decreased level of Prdx5 eRNA transcription in ESDMs (right). Each dot indicates one biological experiment (n = 3 biological repeats from two pooled different experiments; n = 2 biological repeats from two pooled different experiments for B11). ESRRB binding in ES cells is a representative experiment (left) (n = 2 biological repeats). d, Nod2 eRNA transcription was tested in wild-type and mutant (B11, F1, G11) clonal cells of the Prdx5 enhancer. Data from one representative experiment are plotted (n = 2 biological repeats). e, f, Putative Nod2 enhancer mutant sequence diagram and DNA sequence documentation of several of the homozygous mutation clones, used for analysis. g, Two mutant clones (D2, D12) of the putative Nod2 enhancer decreased level of Nod2 eRNA transcription in ESDMs (right). Each dot indicates one biological experiment (n = 3 biological repeats from two pooled different experiments; n = 2 biological repeats from two pooled different experiments for D12). ESRRB binding in ES cells is a representative experiment (left) (n = 2 biological repeats). In the box plots, line shows median and box shows 25th and 75th percentiles. P values calculated using Welch's two-sided t-test. Primer sets are listed in Supplementary Table 2 .
Extended Data Fig. 8 | Premarking in ES cells is required for robust future NPC enhancer activation. a, The putative Nek1 enhancer, referred to as N4; mutant sequence diagram and DNA sequence documentation of several mutation clones (N4C3, N4C16), used for analysis. b, Two mutant clones (N4C3, N4C16) of the N4 enhancer decreased level of N4 eRNA transcription in NPCs (right). Each dot indicates one biological experiment. A representative experiment for ESRRB binding in ES cells is presented (left) (n = 3 biological repeats for N4C3, n = 2 biological repeats for N4C16). c, N8 eRNA transcription was tested in N4 mutant clones (N4C3, N4C16) to show specificity of N4 mutant cells on inhibition of N4 eRNA transcription. A representative experiment is presented (n = 2 biological repeats). d, The putative Ankrd1 enhancer, referred to as N8; mutant sequence diagram and DNA sequence documentation of several of the mutation clones (N8C6, N8C12), used for analysis. e, Two mutant clones (N8C6, N8C12) of the N8 enhancer decreased level of N8 eRNA transcription in NPCs (right). Each dot indicates one biological experiment. ESRRB binding in ES cells is a representative experiment showing inhibition of ESRRB binding in ESRRB-deleted N8 locus (left) (n = 3 biological repeats). f, N4 eRNA transcription was examined to prove the specificity of N8 mutant cells on inhibition of N8 eRNA transcription. Results of one representative experiment are presented (n = 3 biological repeats). g, NPC differentiation was confirmed on day 6 after differentiation by testing expression of ES cell-expressing genes and NPC-expressing genes. A representative experiment is presented (n = 2 biological repeats). In the box plots, line shows median and box shows 25th and 75th percentiles. P values calculated using Welch's two-sided t-test. Primer sets listed in Supplementary Table 2 . Supplementary Table 1 . e, Model of 'premarked' lineage-determining and terminal-differentiation enhancer indicating that poised enhancers bind several ES cell transcription factors, whereas late-activated cell-specific enhancers are premarked by binding of a single ES cell transcription factor, causing chromatin opening, transcription of a non-coding RNA, and appearance of a 5-hmC mark in the area of the enhancer that may provide the molecular memory for what ultimately will be the PU.1-C/EBPα core from which eRNAs will be transcribed. Figure 1a and methods. 6,775 Pu.1+, H3K4me2, ENOS+ macrophage enhancers were selected and this was described in Figure 1c and main text.
Data exclusions
Describe any data exclusions.
No data were excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replications were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups. This is not relevant to this study.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
All the fastq file are generated without the any knowledge of the experimental groups by the UCSD genomics core.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance. Describe the software used to analyze the data in this study.
R is used for statistics.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No unique materials were used.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). c. Report whether the cell lines were tested for mycoplasma contamination.
All cell lines tested were negative for mycoplasma contamination.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
6-8 weeks old female C57BL/6J mice
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
The study did not involve human research participants.
